The recent ban on compounded GLP-1 drugs has put many patients in a difficult situation where they face potentially reduced access to necessary medications. With the costs of standard GLP-1 treatments rising, some patients are contemplating home compounding or medical tourism as alternatives. Comments from the community highlight a trend toward seeking less expensive options abroad, signaling a potential shift in healthcare approaches. There are ethical concerns about the implications of compounding pharmaceuticals and the balance between access and innovation. Additionally, the conversation hints at a broader dissatisfaction with drug pricing and availability, particularly in the U.S., and raises questions about regulatory practices in pharmaceutical manufacturing and distribution.